Comments
Commented by Fabian Lorenz on August 28th, 2024 | 07:30 CEST
Share buyback and buy recommendation! Rheinmetall, Aixtron, Saturn Oil + Gas share
Rheinmetall shares well above EUR 600? At least, that is what analysts believe. However, the share of the armaments group is currently struggling somewhat after reaching an all-time high of over EUR 560. But if Rheinmetall now also conquers space, new record highs should only be a matter of time. Analysts believe Saturn Oil & Gas shares have almost 200% upside potential. The oil company, with a market capitalization of over CAD 500 million, is increasingly becoming a free cash flow monster and now plans to use this for share buybacks. Analysts are also taking a positive view of Aixtron again. The technology company confirmed its forecast at an investor conference. How far can the share rise?
Read
Commented by Stefan Feulner on August 28th, 2024 | 07:15 CEST
Siemens Healthineers, Vidac Pharma, Viking Therapeutics - Powerful movements
After the hype during the COVID-19 pandemic, biotech stocks have lagged behind the broader market, allowing major technology companies to take the lead. Smaller, capital-intensive companies, in particular, have suffered from the high interest rate level. However, this is likely to change soon. On the one hand, monetary policy is expected to be eased, and on the other hand, demographic changes point to a long-term explosion in demand for new medications.
Read
Commented by André Will-Laudien on August 28th, 2024 | 07:00 CEST
Starting signal for a rally? BioNTech, Pfizer, and Bayer under scrutiny, Major news expected from Cardiol Therapeutics and Evotec
Despite all the prophecies of doom, life goes on in the biotech sector. With a medium-term focus, it makes sense to bet on management qualities, as the recent price drops were partially too severe, but the research approaches promise a better future. BioNTech and Pfizer still have to deal with the COVID-19 issue, while Bayer has now taken all measures to achieve a turnaround. The situation at Cardiol Therapeutics and Evotec is particularly interesting, as the members of the Management Board continue to buy shares regularly.
Read
Commented by Stefan Feulner on August 26th, 2024 | 07:30 CEST
BYD, Altech Advanced Materials, Xiaomi - Battle for the gold of the energy transition
The energy transition is underway, and demand for electric vehicles is increasing, albeit more slowly than expected. Lithium has so far been fundamental to the electrification of transportation. To minimize dependence on China, which controls a large part of the mining and processing of the rare metal, the European Union is turning to Serbia, where considerable deposits for battery production lie dormant. However, in addition to lithium-ion batteries, there are alternatives "Made in Germany" that could set the future standard.
Read
Commented by André Will-Laudien on August 26th, 2024 | 07:15 CEST
E-mobility stutters, 200% possible with AI! VW, Mercedes, Prismo Metals, and Super Micro Computer in focus!
E-mobility has become a political issue in Europe. This is because the EU is smilingly having to approve imports from China, which are around 25% cheaper. Although punitive tariffs came into force last week, they also affected German models produced in Asia that are intended for the European market. In the long term, trade wars will always have a negative impact on the economy because consumers remain uncertain, delaying new car purchases. Local dealers are overwhelmed with showroom stock delivered directly from factories. Overall, this puts additional pressure on an already struggling economy, and after Varta, there will likely be more cases of restructuring in the sector. We take a closer look at this challenging sector and uncover interesting opportunities!
Read
Commented by Armin Schulz on August 26th, 2024 | 07:00 CEST
Plug Power, First Hydrogen, thyssenkrupp nucera - Could multiples like in the dot-com era be possible?
The current hydrogen industry is strongly reminiscent of the dot-com era: back then, many internet stocks were considered temporary flops, but some survived and prospered, with Amazon being a prime example. When the dot-com bubble burst, Amazon emerged stronger and became a global economic giant. Similarly, just as there were skeptics about the long-term success of early internet companies, today there are doubts about the long-term viability of hydrogen technology. However, history teaches us that in the midst of many failures, some standout players can emerge that revolutionize the industry and create long-term value. We look at three possible candidates.
Read
Commented by Juliane Zielonka on August 23rd, 2024 | 07:15 CEST
Vidac Pharma, Bavarian Nordic, Palantir - Dream team in travel health and AI: 3 companies in focus
According to Marketresearch.biz, the travel health market is experiencing considerable growth. It is expected to grow from USD 78.5 billion in 2022 to USD 475.8 billion by 2032. This corresponds to an impressive annual growth rate of 20.3% between 2023 and 2032. Travel health can mean avoiding skin cancer while on vacation, but if it does occur, Vidac Pharma is at the forefront with a personalized medicine approach that excites investors. Listening to the WHO, it is clear that monkeypox is once again spreading and posing health risks. As a German-Danish biotech company, Bavarian Nordic has the vaccine answer and is revising its forecasts upwards thanks to strong market demand. Anyone travelling should also keep an eye on geopolitical tensions. Palantir has recently made a name for itself by supporting governments with AI products. Now, Palantir is bringing on board a man with an immense track record in US politics. Today, we focus on three promising investment opportunities.
Read
Commented by Fabian Lorenz on August 23rd, 2024 | 07:00 CEST
Share price jump and share buyback! Rheinmetall, Barrick Gold, Globex Mining
When will the consolidation of Rheinmetall shares end? After jumping to a new all-time high last week, the share price has gone into reverse gear this week. News from Germany and Poland is unsettling investors. What do analysts say? In contrast, Barrick Gold is doing well. Following convincing quarterly figures, the share is on the verge of breaking through a long-standing resistance level. Globex Mining is also benefiting from the gold boom. The mining incubator is impressing with a positive news flow. Can the share buyback program boost the share? Experts see an opportunity for outperformance.
Read
Commented by Juliane Zielonka on August 22nd, 2024 | 07:00 CEST
RWE, dynaCERT, Mercedes-Benz: Energy of the future - Hydrogen vs Electric
The energy transition is at the center of the strategies of RWE, dynaCERT, and Mercedes-Benz, each with different emphases. The energy company RWE is driving forward its hydrogen strategy with billions in investment and state subsidies. The Company plans to build electrolysers and hydrogen storage facilities, which, according to its IR Factbook, are the most promising components of its energy mix in the future. dynaCERT and its portfolio company Cipher Neutron are also focusing on innovative hydrogen solutions. Its AEM electrolysis technology, which is being researched in collaboration with Simon Fraser University, promises more efficient and cost-effective methods of hydrogen production. Mercedes-Benz, on the other hand, is struggling with the weaknesses of electric batteries. A severe fire involving an EV-Mercedes in an underground garage required over 8 hours of firefighting efforts, damaging 108 other vehicles and significantly damaging its reputation in one of its key markets...
Read
Commented by Armin Schulz on August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
Read